Cargando…

Systemic Therapy of Non-Resectable Metastatic Melanoma

In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales: Orouji, Azadeh, Goerdt, Sergij, Utikal, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835112/
https://www.ncbi.nlm.nih.gov/pubmed/24281101
http://dx.doi.org/10.3390/cancers2020955
_version_ 1782292102957236224
author Orouji, Azadeh
Goerdt, Sergij
Utikal, Jochen
author_facet Orouji, Azadeh
Goerdt, Sergij
Utikal, Jochen
author_sort Orouji, Azadeh
collection PubMed
description In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy.
format Online
Article
Text
id pubmed-3835112
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38351122013-11-21 Systemic Therapy of Non-Resectable Metastatic Melanoma Orouji, Azadeh Goerdt, Sergij Utikal, Jochen Cancers (Basel) Review In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy. MDPI 2010-05-26 /pmc/articles/PMC3835112/ /pubmed/24281101 http://dx.doi.org/10.3390/cancers2020955 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Orouji, Azadeh
Goerdt, Sergij
Utikal, Jochen
Systemic Therapy of Non-Resectable Metastatic Melanoma
title Systemic Therapy of Non-Resectable Metastatic Melanoma
title_full Systemic Therapy of Non-Resectable Metastatic Melanoma
title_fullStr Systemic Therapy of Non-Resectable Metastatic Melanoma
title_full_unstemmed Systemic Therapy of Non-Resectable Metastatic Melanoma
title_short Systemic Therapy of Non-Resectable Metastatic Melanoma
title_sort systemic therapy of non-resectable metastatic melanoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835112/
https://www.ncbi.nlm.nih.gov/pubmed/24281101
http://dx.doi.org/10.3390/cancers2020955
work_keys_str_mv AT oroujiazadeh systemictherapyofnonresectablemetastaticmelanoma
AT goerdtsergij systemictherapyofnonresectablemetastaticmelanoma
AT utikaljochen systemictherapyofnonresectablemetastaticmelanoma